Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||transitional cell carcinoma||not applicable||Enfortumab vedotin-ejfv||FDA approved||Actionable||In a Phase II trial (EV-201) that supported FDA approval, Padcev (enfortumab vedotin-ejfv) treatment resulted in an objective response rate of 42% (53/125) with complete response in 9% (11/125) of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy (Journal of Clinical Oncology 37, no. 18_suppl (June 20, 2019) 4505-4505; NCT03219333).||detail...|
|PubMed Id||Reference Title||Details|
|EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.||Full reference...|